https://www.selleckchem.com/products/MLN8237.html
ith primary treatment failure, and 8.3 months (±2.5) in those with secondary treatment failure. Our data show slightly higher persistence levels in patientswith psoriasis and lower discontinuation rates in those without previou****posure to biological therapy. Long-term studies are needed to confirmthese findings and to gain a better understanding of the factors that caninfluence persistence of secukinumab. Our data show slightly higher persistence levels in patients with psoriasis and lower discontinuation rates in those without previou
Giống
Bình luận
Đăng lại
